Pharmafile Logo

Charles River

For more than 60 years, Charles River has provided tailored research models and laboratory animal support services, as well as preclinical and clinical support services, to help our global partners accelerate their research and drug development efforts. Our offerings span the entire drug development process, from discovery through market approval, forming a seamless partnership throughout the process.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Company Details

Charles River Laboratories International, Inc., 251 Ballardvale Street, Wilmington, MA 01887, USA
+800.3195.3430

 Latest Content from PMHub 

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

The Heart of the Matter: Medscape Education’s Cardiology Footprint at ESC 2026

For more than 30 years, Medscape Education has built independent, accredited cardiovascular education designed around one goal: improved patient outcomes. This year at the European Society of Cardiology Congress (ESC...

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

What do patient stories actually teach us?

Press Releases | July 21, 2026 | Mednet

How do we translate individual experiences into support that helps others and create support that feels personal but remains relevant to many?

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

More Than Pink Walls: What Women-Centric Care Actually Requires

The phrase "patient-centered care" is tossed around freely in healthcare corporate boardrooms. Yet, for more than half the population, that promise routinely fractures. In the latest episode of the Hear...

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization

Press Releases | July 14, 2026 | Real Chemistry

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.